Cardiovascular SystemVASSTNCT05727332
Vascular Adaptations to Single-Sprint Training
A study testing Single-Sprint Training in people with Cardiovascular System, run by University of Mississippi, Oxford at 1 site in United States.
Trial summary
The long-term objective of this research line is to identify and implement an effective and feasible intervention capable of preventing and/or reducing the burden of cardiometabolic and obesity-related diseases that affect Mississippians and others. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular System
- What is being tested?
- Single-Sprint Training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Jun 2023to 5 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18-35 years
- Untrained (no regular exercise engagement for the previous 6 months)
- Healthy enough to begin exercise (assessed via Physical Activity Readiness Questionnaire)
Who cannot join
- Illness/injury preventing cycling exercise
- Prescribed medication to control heart rate
- Prescribed medication to control blood pressure
- Use of nicotine within the previous 6 months
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Mississippi
University, Mississippi, 38677
About this study
The long-term objective of this research line is to identify and implement an effective and feasible intervention capable of preventing and/or reducing the burden of cardiometabolic and obesity-related diseases that affect Mississippians and others. The pursuit of this long-term objective will begin with achieving the specific aims proposed in this pilot project, which are to determine the effect of single sprint training for improving (1) systemic macro-vascular function, (2) local and systemic micro-vascular function, and (3) cardiorespiratory fitness. These aims will be achieved using a randomized controlled trial whereby 40 males and females will be randomized into an intervention group (n=20) or time-matched negative control group (n=20). The intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks and the control group will be asked to maintain pre-intervention habits/behavior over 4 weeks. All outcome measures are non-invasive, and will be assessed pre-, mid-, and post-intervention, with the exception of cardiorespiratory fitness, which will be measured pre- and post-. To achieve aim 1, brachial artery flow-mediated dilation via ultrasonography and systolic and diastolic blood pressure via automated oscillometry will be measured on the arm. To achieve aim 2, post-occlusive reactive hyperemia via near-infrared spectroscopy and reactive hyperemia via ultrasound will be measured in the arm and leg, respectively. To achieve aim 3, pulmonary gas exchange will be measured during a graded exercise test on a cycle ergometer. All outcomes will be compared across time between conditions and sex with a three-way Bayesian Repeated Measures ANOVA using pre-values as covariates and an uninformed prior. 95% credible intervals will also be calculated to power future investigations using this intervention. If the intervention is found effective, future studies will be conducted to determine the efficacy of the intervention in larger groups and more clinical populations, and to determine the mechanisms mediating the adaptations. If ineffective, the knowledge gained will be used to develop future interventions.
- Conditions
- Cardiovascular System
- Being tested
- Single-Sprint Training
- Keywords
- Vascular, Cardiorespiratory Fitness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Single-Sprint TrainingBehavioural
A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | The intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks. Receives: Behavioral: Single-Sprint Training |
| Time-Matched Control | No intervention | The control group will be asked to maintain pre-intervention habits/behavior over 4 weeks. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline systemic macrovascular function at 2 weeks and 4 weeks
Systemic macrovascular changes will be quantified by measuring 1) brachial artery flow-mediated dilation via vascular ultrasound, and 2) resting brachial blood pressure via a standard automated blood pressure cuff.
Measured: week 0, week 2, and week 4
Change from baseline local and systemic microvascular function at 2 weeks and 4 weeks
Systemic changes in microvascular endothelial function will be quantified by using the post-occlusive reactive hyperemia technique in the arm. Local microvascular function will be measured using the passive leg movement technique for reactive hyperemia and post-occlusive reactive hyperemia in the leg.
Measured: week 0, week 2, and week 4
Secondary outcomes (1)
Change from baseline maximal oxygen consumption at 2 weeks and 4 weeks
To assess changes in cardiorespiratory fitness, pulmonary gas exchange data will be collected during a maximal graded exercise test on a cycle ergometer. VO2max and ventilation thresholds will be reported in accordance with current guidelines.
Measured: week 0, week 2, and week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2023
- Study start5 Jun 2023
- Primary completion31 Jul 2024
- Study completion5 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular SystemStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Intervention group and negative control group
- Masking
- None (open label)
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Mississippi, Oxford
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Matthew Jessee, University of Mississippi, Oxford
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05727332
- Sponsor's protocol ID
- U54GM115428
- Acronym
- VASST
- Status last verified
- Jun 2025
- First submitted
- 26 Jan 2023
- Last updated
- 26 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no current plan to share individual data outside of the investigators responsible for conducting the study. If data are requested, they will only be shared after being de-identified, unless otherwise required by law.
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vascular Adaptations to Single-Sprint Training
- ClinicalTrials.gov ID
- NCT05727332
- Acronym / sponsor ID
- VASST / U54GM115428
- Conditions
- Cardiovascular System
- Keywords
- Vascular, Cardiorespiratory Fitness
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- University of Mississippi, OxfordUniversity, hospital or other
- Study start
- 5 Jun 2023 (actual)
- Primary completion
- 31 Jul 2024 (actual)
- Study completion
- 5 Dec 2024 (actual)
- First posted
- 14 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The long-term objective of this research line is to identify and implement an effective and feasible intervention capable of preventing and/or reducing the burden of cardiometabolic and obesity-related diseases that affect Mississippians and others. The pursuit of this long-term objective will begin with achieving the specific aims proposed in this pilot project, which are to determine the effect of single sprint training for improving (1) systemic macro-vascular function, (2) local and systemic micro-vascular function, and (3) cardiorespiratory fitness. These aims will be achieved using a randomized controlled trial whereby 40 males and females will be randomized into an intervention group (n=20) or time-matched negative control group (n=20). The intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks and the control group will be asked to maintain pre-intervention habits/behavior over 4 weeks. All outcome measures are non-invasive, and will be assessed pre-, mid-, and post-intervention, with the exception of cardiorespiratory fitness, which will be measured pre- and post-. To achieve aim 1, brachial artery flow-mediated dilation via ultrasonography and systolic and diastolic blood pressure via automated oscillometry will be measured on the arm. To achieve aim 2, post-occlusive reactive hyperemia via near-infrared spectroscopy and reactive hyperemia via ultrasound will be measured in the arm and leg, respectively. To achieve aim 3, pulmonary gas exchange will be measured during a graded exercise test on a cycle ergometer. All outcomes will be compared across time between conditions and sex with a three-way Bayesian Repeated Measures ANOVA using pre-values as covariates and an uninformed prior. 95% credible intervals will also be calculated to power future investigations using this intervention. If the intervention is found effective, future studies will be conducted to determine the efficacy of the intervention in larger groups and more clinical populations, and to determine the mechanisms mediating the adaptations. If ineffective, the knowledge gained will be used to develop future interventions.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Intervention group and negative control group
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Single-Sprint TrainingThe intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks. |
| Time-Matched Control | No intervention | –The control group will be asked to maintain pre-intervention habits/behavior over 4 weeks. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age 18-35 years
- Untrained (no regular exercise engagement for the previous 6 months)
- Healthy enough to begin exercise (assessed via Physical Activity Readiness Questionnaire)
Key exclusion criteria (4 listed)
- Illness/injury preventing cycling exercise
- Prescribed medication to control heart rate
- Prescribed medication to control blood pressure
- Use of nicotine within the previous 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Single-Sprint TrainingA single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks | Behavioural | Intervention |
Primary outcome
Change from baseline systemic macrovascular function at 2 weeks and 4 weeks
Time frame: week 0, week 2, and week 4
Systemic macrovascular changes will be quantified by measuring 1) brachial artery flow-mediated dilation via vascular ultrasound, and 2) resting brachial blood pressure via a standard automated blood pressure cuff.
Change from baseline local and systemic microvascular function at 2 weeks and 4 weeks
Time frame: week 0, week 2, and week 4
Systemic changes in microvascular endothelial function will be quantified by using the post-occlusive reactive hyperemia technique in the arm. Local microvascular function will be measured using the passive leg movement technique for reactive hyperemia and post-occlusive reactive hyperemia in the leg.
1 secondary outcome
Change from baseline maximal oxygen consumption at 2 weeks and 4 weeks
Time frame: week 0, week 2, and week 4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2025.
- Individual participant dataSharing planned: No. There is no current plan to share individual data outside of the investigators responsible for conducting the study. If data are requested, they will only be shared after being de-identified, unless otherwise required by law.
Related trials for Cardiovascular System
Recruiting
Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
ST-Elevation Myocardial Infarction (STEMI)
RecruitingPhase 3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Active, not recruitingObservational study
EFFECT OF HYBRID CLOSED-LOOP SYSTEMS ON CARDIOVASCULAR MARKERS IN TYPE 1 DIABETES.
Type 1 Diabetes
RecruitingPhase 4
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Hypertensive Disorders of Pregnancy, Preeclampsia
Active, not recruiting
Insulin Resistance and Coronary Microvascular Dysfunction in Patients With Myocardial Ischemia and Non-obstructive Coronary Artery Disease
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Single-Sprint Training in people with Cardiovascular System, run by University of Mississippi, Oxford at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline systemic macrovascular function at 2 weeks and 4 weeks (time frame: week 0, week 2, and week 4). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2025.